BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 885 filers reported holding BAXTER INTL INC in Q3 2023. The put-call ratio across all filers is 0.40 and the average weighting 0.2%.
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $222,925 | -4.3% | 4,893 | +63.1% | 0.05% | -26.0% |
| Q1 2022 | $233,000 | -9.7% | 3,000 | 0.0% | 0.07% | -8.8% |
| Q4 2021 | $258,000 | +7.1% | 3,000 | 0.0% | 0.08% | 0.0% |
| Q3 2021 | $241,000 | -37.6% | 3,000 | -37.5% | 0.08% | -34.4% |
| Q2 2021 | $386,000 | -4.7% | 4,800 | 0.0% | 0.12% | -11.6% |
| Q1 2021 | $405,000 | +5.2% | 4,800 | 0.0% | 0.14% | -4.2% |
| Q4 2020 | $385,000 | -0.3% | 4,800 | 0.0% | 0.14% | -16.3% |
| Q3 2020 | $386,000 | -6.5% | 4,800 | 0.0% | 0.17% | -11.8% |
| Q2 2020 | $413,000 | +5.9% | 4,800 | 0.0% | 0.20% | -10.1% |
| Q1 2020 | $390,000 | -2.7% | 4,800 | 0.0% | 0.22% | +46.6% |
| Q4 2019 | $401,000 | -4.5% | 4,800 | 0.0% | 0.15% | -7.5% |
| Q3 2019 | $420,000 | +6.9% | 4,800 | 0.0% | 0.16% | +21.2% |
| Q2 2019 | $393,000 | +0.8% | 4,800 | 0.0% | 0.13% | -5.0% |
| Q1 2019 | $390,000 | +23.4% | 4,800 | 0.0% | 0.14% | +12.1% |
| Q4 2018 | $316,000 | -14.6% | 4,800 | 0.0% | 0.12% | +3.3% |
| Q3 2018 | $370,000 | +4.5% | 4,800 | 0.0% | 0.12% | -4.8% |
| Q2 2018 | $354,000 | +13.5% | 4,800 | 0.0% | 0.13% | +23.5% |
| Q1 2018 | $312,000 | -2.5% | 4,800 | -3.0% | 0.10% | -1.0% |
| Q4 2017 | $320,000 | +2.9% | 4,950 | 0.0% | 0.10% | +5.1% |
| Q3 2017 | $311,000 | +3.7% | 4,950 | 0.0% | 0.10% | -3.0% |
| Q2 2017 | $300,000 | +16.7% | 4,950 | 0.0% | 0.10% | +16.1% |
| Q1 2017 | $257,000 | +17.4% | 4,950 | 0.0% | 0.09% | +16.0% |
| Q4 2016 | $219,000 | -9.9% | 4,950 | -2.9% | 0.08% | -3.8% |
| Q3 2016 | $243,000 | +5.2% | 5,100 | 0.0% | 0.08% | +1.3% |
| Q2 2016 | $231,000 | +10.0% | 5,100 | 0.0% | 0.08% | +6.9% |
| Q1 2016 | $210,000 | -41.2% | 5,100 | 0.0% | 0.07% | -32.1% |
| Q2 2015 | $357,000 | -1.7% | 5,100 | -3.8% | 0.11% | 0.0% |
| Q1 2015 | $363,000 | -6.4% | 5,300 | 0.0% | 0.11% | -13.1% |
| Q4 2014 | $388,000 | +2.1% | 5,300 | 0.0% | 0.12% | +7.0% |
| Q3 2014 | $380,000 | -0.8% | 5,300 | 0.0% | 0.11% | +1.8% |
| Q2 2014 | $383,000 | -3.5% | 5,300 | -1.9% | 0.11% | -9.7% |
| Q1 2014 | $397,000 | +5.6% | 5,400 | 0.0% | 0.12% | +4.2% |
| Q4 2013 | $376,000 | +5.9% | 5,400 | 0.0% | 0.12% | +0.8% |
| Q3 2013 | $355,000 | -5.1% | 5,400 | 0.0% | 0.12% | -9.9% |
| Q2 2013 | $374,000 | – | 5,400 | – | 0.13% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SECTOR GAMMA AS | 713,500 | $49,895,000 | 12.74% |
| Veritas Asset Management LLP | 7,636,450 | $534,017,000 | 7.53% |
| FIRST NEW YORK SECURITIES LLC /NY | 154,158 | $10,780,269,000 | 5.40% |
| Gabalex Capital Management LLC | 200,000 | $14,981,000 | 5.39% |
| Veritas Investment Management LLP | 291,825 | $18,816,000 | 5.32% |
| Tweedy, Browne Co LLC | 2,543,966 | $177,900,000 | 4.91% |
| York Capital Management Global Advisors, LLC | 8,074,375 | $564,641,000 | 4.78% |
| First Fiduciary Investment Counsel, Inc. | 270,675 | $18,928,000 | 4.10% |
| SCHARF INVESTMENTS, LLC | 2,247,225 | $157,148,000 | 4.03% |
| Osher Van de Voorde Investment Management | 96,235 | $6,730,000 | 3.91% |